0005 Epigallocatechin-3-gallate decreases VASP expression and MCF-7 cells invasion by inhibiting Rac1 activity

Abstract

We investigated whether hypermethylation identifies breast cancers with distinctive clinical and pathological features. Methods: We evaluated the methylation of RASSF1A, SYK, DAPK, ER-a, BRCA1, CCND2, p16, TMS1, ITIH5 and APC in 95 breast carcinomas using methylation-specific PCR. Results: Methylation frequencies ranged from 9.1% for SYK to 95.8% for RASSF1A. For all age patients, tumors with CCND2 methylation were associated with triple negative (OR=1.34, CI: 1.165−1.541). However, tumors of patient’s age younger than 50 with BRCA1 methylation were associated with ER (OR=7, CI: 1.277−38.358) or PR negative (OR=11.07, CI: 1.245–98.598). And DAPK methylation was associated p53 mutation (OR=2.714, CI: 1.507−4.890). Nevertheless, for patient’s age older than 50, tumors with ITIH5 and BRCA1 methylation were associated with more advanced t stage (t0−1/t2−4, ITIH5 OR= 0.283, CI= 0.088−0.910; BRCA1 OR= 0.3, CI= 0.095−0.948) and the methylation of APC was associated with PR negative (OR=4.52, CI= 1.203−16.967). Conclusion: Our data suggests that gene methylation may be linked to various pathological features of breast cancer. Furthermore, the different methylation profile in tumors of different age patient population may imply different carcinogenesis pathway, however, this requires confirmation in larger studies.